David Dismuke, Ph.D., Forge's Chief Technical Officer will be presenting at Gene Therapy for Ophthalmic disorders on "Efficient Manufacturing for Ocular Diseases".
Date: September 23
Time: 10:30 am ET
Watch: https://genetherapy-ophthalmology.com/
Turnkey, scalable, premier research-grade AAV production.
End-to-end capabilities from research to cGMP grade, reducing the need for bridging studies.
Fully disposable, closed-system processing.
Our mission is to enable access to life changing gene therapies and help bring them from idea into reality. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them the most.